Immuneering Corporation

The post Deep Cyclic Inhibition of MEK in RAS-mutant Tumors: Constraining MAPK-Axis Escape and Preserving Combination Optionality appeared first on Immuneering Corporation.

Aja Harbert joined Immuneering as a Senior Director, People in July 2026. Ms. Harbert is an HR leader with broad experience supporting entrepreneurial, startup, and high-growth organizations. Her background spans biotechnology, venture capital, and private equity, where she partners with leadership teams to build scalable organizations and people strategies. She has worked with organizations across North America, Europe, and Asia. Aja is passionate about […] The post Aja Harbert appeared first on Immuneering Corporation.

Paris Offor joined Immuneering as a Senior Research Associate in July 2026 with over five years of experience in in-vitro pharmacology, translational cancer research, and preclinical drug development. She has contributed to numerous preclinical oncology studies in the past by applying expertise in both advanced mammalian and patient-derived xenograft (PDX) cell culture, flow cytometry, high-content imaging, and molecular biology techniques. Paris has a strong foundation in […] The post Paris Offor appeared first on Immuneering Corporation.

David joined Immuneering as Vice President, Corporate Communications in July 2026. He is a senior corporate communications leader with expertise in corporate media relations, patient advocacy, executive, financial and crisis communications, as well as issues management. Prior to joining Immuneering, David held communication leadership roles at Pfizer, Seagen, Biogen, City of Hope, Amgen, Merck and Disney. He earned a BA in journalism from the University of Maine and holds a management certificate […] The post David Caouette appeared first on Immuneering Corporation.

The post Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF-Bypass appeared first on Immuneering Corporation.

David joined Immuneering in 2026 as Senior Research Associate. Prior to joining Immuneering, David worked at Escient Pharmaceuticals, where he ran high-throughput screening and helped bring the company’s lead project to the clinic. David earned his B.S. in Biology from UCSD.   The post David Freeman appeared first on Immuneering Corporation.

Jennifer joined Immuneering as Associate Director, Clinical Scientist in 2026. She has over a decade of experience in oncology clinical trials, with prior experience as a Clinical Scientist on Phase I-III trials at Novartis, Celgene, and Regeneron. Jennifer also has site experience as a Research Pharmacist at Jacobi Medical Center and as a Study Coordinator at Dana-Farber Cancer Institute, as well […] The post Jennifer Cho appeared first on Immuneering Corporation.

Jyoti joined Immuneering as Director, Quality Systems and Compliance in 2026. She brings more than 14 years of quality assurance and quality systems experience in the biotech industry, including building quality management systems from the ground up. Prior to joining Immuneering , she held quality roles at SpringWorks Therapeutics, Resilience, bluebird bio, Organon Teknika, and Merck. Jyoti holds an M.S. in Environmental Science from the University of North […] The post Jyoti Joshi appeared first on Immuneering Corporation.

Dr Ahn on Phase 2a Data With Atebimetinib and Chemotherapy in Pancreatic Cancer The post June 2026 – OncLive appeared first on Immuneering Corporation.

Atebimetinib Plus Modified Gemcitabine/Nab-Paclitaxel Shows Encouraging Efficacy, Tolerability in First-Line Metastatic PDAC The post June 2026 – OncLive appeared first on Immuneering Corporation.